We seek $10M Seed funding and aim to have a company valuation of $1.7B by 2032 with a projected growing EBITDA of $245M. We see a huge, stable market. The lack of sovereign CMOs worldwide makes most countries dependent on non-national sources for even the most basic needed drugs. Our strategic plan builds national resilience, creates a sustainable foundation for further growth, generates business focused on good patient outcomes at fair prices, and addresses national security needs
As a result of our successful experience since 2016, Interbiome Partners, LLC, has created a near-disruptive business model and now seeks $10M seed funding for the renovation and equipage completion of our 26,000 sq ft CdMO (CMO of the Future) facility in Rockville, MD, and to have a runway for “A” round funding. Our strategic plan is to build many re-configurable CMOFs that leverage the benefits of advanced/standardized features to significantly reduce operating costs and risks and increase facility and workforce agility. To further lower operating costs and ensure sustainability, follow-on CMOFS may be in OPPORTUNITY ZONES (OZ). Investors pay no US capital gains tax if they hold the OZ investment for ten years or more. This strategy creates a two-fold benefit: creating a stable reserve facility/workforce capacity operating at a lower cost and a secure base for acquisition and expansion and the ability to self-fund further domestic and Global growth. Once attaining FDA GMP certification, our initial manufacturing focus will include the sustainable manufacture of needed but neglected or abandoned drugs which is a very stable business.
Ready to Ask For Funding for your company?
Post a Funding Request